Murphy R L
HIV Treatment Unit, Northwestern University Medical School, Chicago, Illinois, USA.
Antivir Ther. 1999;4 Suppl 3:85-7.
Preliminary results are presented from a dose-comparison trial of the regimen stavudine/lamivudine plus the novel protease inhibitor, ABT-378/ritonavir, given to 101 antiretroviral-naive, human immunodeficiency virus (HIV)-infected subjects for > or = 24 weeks. The HIV-1 RNA had decreased to <400 copies/ml in 94% of patients and CD4 cell count had increased by approximately 160 cells/mm3 at 24 weeks. The regimen was well tolerated and merits further study.
初步结果来自一项剂量比较试验，该试验将司他夫定/拉米夫定方案与新型蛋白酶抑制剂ABT-378/利托那韦联合应用于101名未接受过抗逆转录病毒治疗的人类免疫缺陷病毒（HIV）感染受试者，治疗时间≥24周。在24周时，94%的患者HIV-1 RNA降至<400拷贝/毫升，CD4细胞计数增加了约160个细胞/立方毫米。该方案耐受性良好，值得进一步研究。
